The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

10 articles for V Pendharkar


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Optimization of a Porcupine Inhibitor.EBI
Experimental Therapeutics Centre
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.EBI
Experimental Therapeutics Centre
Fragment-based ligand design of novel potent inhibitors of tankyrases.EBI
Nanyang Technological University
Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.EBI
Experimental Drug Development Centre
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.EBI
A*Star
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.EBI
Experimental Drug Development Centre
Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.EBI
Experimental Therapeutics Centre
Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.EBI
Agency For Science, Technology and Research (A*Star)
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.EBI
Agency For Science, Technology and Research (A*Star)
Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.EBI
Experimental Therapeutics Centre